[go: up one dir, main page]

AR059127A1 - Terapeutica combinada con anticuerpos anti-egfr y anti-her2 - Google Patents

Terapeutica combinada con anticuerpos anti-egfr y anti-her2

Info

Publication number
AR059127A1
AR059127A1 ARP070100020A ARP070100020A AR059127A1 AR 059127 A1 AR059127 A1 AR 059127A1 AR P070100020 A ARP070100020 A AR P070100020A AR P070100020 A ARP070100020 A AR P070100020A AR 059127 A1 AR059127 A1 AR 059127A1
Authority
AR
Argentina
Prior art keywords
her2
antibody
egfr
combined
cancer
Prior art date
Application number
ARP070100020A
Other languages
English (en)
Inventor
Stephen D Gillies
David Azria
Christel Larbouret
Andre Pelegrin
Original Assignee
Inst Nat Sante Rech Med
Merck Patent Gmbh
Ct Regional De Lutte Contre Le
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37876938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059127(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med, Merck Patent Gmbh, Ct Regional De Lutte Contre Le filed Critical Inst Nat Sante Rech Med
Publication of AR059127A1 publication Critical patent/AR059127A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso combinado de anticuerpo anti-EGFR y anticuerpo anti-Her2 para el tratamiento de cáncer; especialmente se refiere al tratamiento combinado mediante anticuerpo monoclonal ômatuzumabö (hmAB 425, EMD 72000) dirigido contra receptores EGF y ôtrastuzumabö (HERCEPTIN«) dirigido contra los receptores HER2. El tratamiento combinado es adecuado para pacientes que sufren cáncer, especialmente en donde HER2 se expresa en baja cantidad, de preferencia cáncer de páncreas. Reivindicacion 1: Una composicion farmacéutica que comprende un anticuerpo anti-EGFR y un anticuerpo anti-HER2 (ErbB2) o sus fragmentos inmunologicamente efectivos en una cantidad efectiva opcionalmente junto con un portador, diluyente o excipiente farmacéutico, en donde el anticuerpo anti-EGFR es mAb 425 murino, quimérico o humanizado (matuzumab), y el anticuerpo anti-HER2 es mAb 4D5 murino, quimérico o humanizado(trastuzumab).
ARP070100020A 2006-01-04 2007-01-03 Terapeutica combinada con anticuerpos anti-egfr y anti-her2 AR059127A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06000107 2006-01-04

Publications (1)

Publication Number Publication Date
AR059127A1 true AR059127A1 (es) 2008-03-12

Family

ID=37876938

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100020A AR059127A1 (es) 2006-01-04 2007-01-03 Terapeutica combinada con anticuerpos anti-egfr y anti-her2

Country Status (13)

Country Link
US (2) US20090214541A1 (es)
EP (1) EP1968633B2 (es)
JP (1) JP2009522316A (es)
KR (1) KR20080110987A (es)
CN (1) CN101365486B (es)
AR (1) AR059127A1 (es)
AU (1) AU2006332212B8 (es)
BR (1) BRPI0620888A2 (es)
CA (1) CA2636074A1 (es)
EA (1) EA015173B1 (es)
MX (1) MX2008008564A (es)
WO (1) WO2007076923A1 (es)
ZA (1) ZA200806723B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
ES2609094T3 (es) 2007-01-25 2017-04-18 Dana-Farber Cancer Institute, Inc. Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante
JP5618549B2 (ja) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
MX2010001757A (es) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
KR101642846B1 (ko) * 2007-12-26 2016-07-26 백시넥스 인코포레이티드 항-ｃ35 항체 병용 치료 및 방법
AR073538A1 (es) * 2008-09-03 2010-11-17 Genentech Inc Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
US8883149B2 (en) 2008-09-15 2014-11-11 Yeda Research And Development Co. Ltd. Antibody combinations and use of same for treating cancer
US8728479B2 (en) * 2009-03-31 2014-05-20 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
JP6184695B2 (ja) * 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
US8609095B2 (en) * 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
WO2012156975A1 (en) 2011-05-16 2012-11-22 Yeda Research And Development Co. Ltd. COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
US9527913B2 (en) 2012-05-02 2016-12-27 Symphogen A/S Humanized pan-HER antibody compositions
US10562974B2 (en) 2013-03-13 2020-02-18 University Of Kentucky Research Foundation Methods of administering IgG1 antibodies and methods of suppressing angiogenesis
WO2014139131A1 (en) * 2013-03-14 2014-09-18 Crown Bioscience, Inc. Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents
WO2015006736A2 (en) * 2013-07-11 2015-01-15 The California Institute For Biomedical Research Coiled coil immunoglobulin fusion proteins and compositions thereof
KR20160083949A (ko) 2013-11-13 2016-07-12 자임워크스 인코포레이티드 Egfr 및/또는 her2를 표적화하는 1가 항원 결합 작제물 및 이의 용도
CA2951604A1 (en) * 2014-08-29 2016-03-03 Pablo Umana Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
CN104991065B (zh) * 2015-07-07 2017-01-11 复旦大学附属金山医院 一种用于诊断乳腺癌的三联标志物及其应用
JP2018062980A (ja) * 2016-10-12 2018-04-19 株式会社ジェイテクト ボールネジ装置、ボールネジ装置の製造方法及びステアリング装置
JP6914336B2 (ja) * 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
CN117915950A (zh) * 2021-08-06 2024-04-19 甘李药业股份有限公司 一种多特异性抗体及其用途
CN117430707B (zh) * 2023-10-25 2024-04-19 重庆天科雅生物科技有限公司 一种cik细胞的制备方法及其在治疗癌症中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
ATE247168T1 (de) * 1991-03-06 2003-08-15 Merck Patent Gmbh Humanisierte monoklonale antikörper
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
CN1703243B (zh) * 2002-10-10 2011-05-04 默克专利有限公司 针对erb-b1受体的药物组合物
JP2007522157A (ja) * 2004-02-12 2007-08-09 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗ｅｇｆｒ抗体の高濃縮液体製剤
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her

Also Published As

Publication number Publication date
MX2008008564A (es) 2009-01-29
JP2009522316A (ja) 2009-06-11
EP1968633B2 (en) 2017-11-01
US9522956B2 (en) 2016-12-20
BRPI0620888A2 (pt) 2011-11-29
CN101365486A (zh) 2009-02-11
AU2006332212A1 (en) 2007-07-12
AU2006332212B2 (en) 2013-03-28
EA200870141A1 (ru) 2009-02-27
EP1968633A1 (en) 2008-09-17
EP1968633B1 (en) 2014-02-12
CN101365486B (zh) 2012-10-31
ZA200806723B (en) 2009-09-30
EA015173B1 (ru) 2011-06-30
WO2007076923A1 (en) 2007-07-12
CA2636074A1 (en) 2007-07-12
US20150132308A1 (en) 2015-05-14
AU2006332212B8 (en) 2013-05-30
KR20080110987A (ko) 2008-12-22
US20090214541A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
AR059127A1 (es) Terapeutica combinada con anticuerpos anti-egfr y anti-her2
PE20100251A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
IL276695A (en) Antibodies, pharmaceutical compositions and uses thereof
JP2017149720A5 (es)
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
PE20081179A1 (es) Formulaciones estables de anticuerpos egfr
ES2523194T3 (es) Anticuerpo monoclonal humano específico para cada tumor
PE20121397A1 (es) Anticuerpos especificos para cadherina-17
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20191546A1 (es) Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb
BRPI0508716A (pt) anticorpo monoclonal, processo para produzir o mesmo, composição farmacêutica, e, uso de um anticorpo monoclonal
JP2015506912A5 (es)
NZ578943A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
EP1865058A4 (en) MONOCLONAL ANTIBODY ANTI-CD-20
AR047611A1 (es) Formulaciones liquidas de anticuerpos anti-egfr altamente concentradas
PE20091024A1 (es) Anticuerpos monoclonales que se unen a anexelekto y sus usos
PE20120622A1 (es) Anticuerpos anti-vegf y sus usos
PE20091269A1 (es) Moleculas de union al receptor ox40 humano
PA8650001A1 (es) Formulaciones de anticuerpo
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
NZ568403A (en) CD20-specific antibodies and methods of employing same
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
RU2012128343A (ru) АНТИ-С4.4а АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
NZ595011A (en) Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases

Legal Events

Date Code Title Description
FB Suspension of granting procedure